You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 7,795,504

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,795,504

Title:	Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
Abstract:	The present invention is directed to nucleic acid molecules and nucleic acid constructs, and other agents associated with simultaneous up- and down-regulation of expression of RNAs. Specifically it includes methods of simultaneously enhancing the expression of a first RNA at the same time as suppressing the expression of a second RNA. The present invention also specifically provides constructs capable of simultaneously enhancing the expression of a first RNA while at the same time suppressing the expression of a second RNA, methods for utilizing such agents and plants containing such agents. The present invention also provides other constructs including polycistronic constructs.
Inventor(s):	Van Eenennaam; Alison (Davis, CA), Shewmaker; Christine K. (Woodland, CA)
Assignee:	Monsanto Technology LLC (St. Louis, MO)
Application Number:	11/633,469
Patent Claims:	1. A nucleic acid molecule comprising a first nucleic acid segment encoding a polypeptide, and a second nucleic acid segment for suppression of a polypeptide involved in altering oleic acid content in a plant cell, wherein transcription of said nucleic acid molecule in said cell results in the simultaneous expression of the polypeptide and suppression of fatty acid desaturation in said cell, and wherein said first nucleic acid segment and said second nucleic acid segment are operably linked to a single promoter in a polycistronic configuration. 2. The nucleic acid molecule according to claim 1, wherein said second nucleic acid segment for suppression of a polypeptide involved in altering oleic acid content in a host cell comprises DNA from a FAD2 gene. 3. The nucleic acid molecule according to claim 2, wherein said second nucleic acid segment is expressed as a dsRNA molecule. 4. The nucleic acid molecule according to claim 3, wherein said second nucleic acid segment has at least 21 contiguous nucleotides complementary to the mRNA of the FAD2 gene. 5. The nucleic acid molecule according to claim 4, wherein said second nucleic acid segment has at least 21 contiguous nucleotides from an intron in said FAD2 gene. 6. A plant having in its genome a nucleic acid molecule of claim 1. 7. A soybean plant having in its genome a nucleic acid molecule of claim 1.

Details for Patent 7,795,504

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2023-09-24
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2023-09-24
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2023-09-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.